Compare PRVA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | WVE |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2021 | 2015 |
| Metric | PRVA | WVE |
|---|---|---|
| Price | $21.50 | $13.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $30.50 | $30.44 |
| AVG Volume (30 Days) | 653.1K | ★ 2.8M |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,736,390,000.00 | $3,704,000.00 |
| Revenue This Year | $23.19 | N/A |
| Revenue Next Year | $13.51 | $15.93 |
| P/E Ratio | $197.27 | ★ N/A |
| Revenue Growth | 4.74 | ★ 149.43 |
| 52 Week Low | $18.78 | $5.28 |
| 52 Week High | $26.51 | $21.73 |
| Indicator | PRVA | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 50.35 |
| Support Level | $19.54 | $12.53 |
| Resistance Level | $24.04 | $14.56 |
| Average True Range (ATR) | 0.73 | 0.75 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 27.50 | 47.56 |
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.